US News Pediatric Survey

About the Phase 3 Registration Program for the Treatment of NASH (Non-alcoholic steatohepatitis) Analyses from the resmetirom Phase 2 NASH study demonstrate that the magnitude of liver fat reduction accurately predicts NASH resolution and liver fibrosis reduction and, specifically, that the resmetirom doses being used in Madrigal’s Phase 3 ... ................
................